Using antagonist of endothelial cell-specific molecule-1 for treating cancer, e.g. of the respiratory tract, particularly monoclonal antibodies

摘要

Use of an antagonist (I) of endothelial cell-specific molecule-1 (II) for treatment of cancer, is new. Independent claims are also included for the following: (1) antagonist of (II) that is the monoclonal antibody produced by hybridoma MEC15 (CNCM I-2572); and (2) methods for selecting (I).